Biological Hazard Monitoring Innovators Team to Distribute Systems for Rapid Biothreat Assessment

Business Wire, March 17, 2008

Innovative Biosensors, Inc. and Universal Detection Technology Partner on Biological Detection and Identification Systems for Environmental Monitoring

ROCKVILLE, Md. & LOS ANGELES -- Two bio-monitoring technology producers have come together to address the market need for biothreat detectors for clients dependent on accurate, rapid environmental assessments.

Innovative Biosensors, Inc. (IBI) of Rockville, MD, a company developing rapid, ultra-sensitive tests to identify harmful pathogens and Universal Detection Technology, (UDT) a developer of early-warning monitoring technologies announced they will team to market and distribute their respective and complimentary products to protect people from bioterrorism threats in indoor and outdoor environments.

Under the agreement, both IBI and UDT will market and distribute their partner's biodetection equipment, in addition to their own products, broadening their respective abilities to develop complete solutions for building and other security applications across government, military and commercial markets.

IBI's proprietary BioFlash biological identifier is rugged, portable, and incorporates a high-volume aerosol sampler. This integrated technology provides rapid, specific and sensitive identification of up to 21 biological threat agents in single test or multi-test formats in less than five minutes.

"IBI's BioFlash is the first, fully integrated system which combines collection and real-time identification functions, to provide rapid and cost-effective detection and identification of biological threat agents," said Rick Thomas, Vice President of Business Development for IBI. "IBI's strategic goal is to continue to evolve through the expansion of our current BioFlash technology system along with partners such as UDT, to provide total issue encompassing solutions for both military and civilian biothreat protection."

UDT's BSM-2000 is an autonomous air monitoring system capable of detecting abnormal levels of airborne bacterial spores such as anthrax. The BSM-2000 technology has been developed by NASA's Jet Propulsion Laboratory and has been used in NASA's Planetary Protection Program before being modified by UDT for use in bioterrorism detection. The BSM-2000 combines a bioaerosol capture device with a simple and robust chemical test for bacterial spores that is completely automated.

"We are very excited to join forces with IBI and we look forward to actively co-market our technologies to users in the United States and around the world," said Mr. Jacques Tizabi, UDT's Chief Executive Officer.

About Innovative Biosensors, Inc.

Innovative Biosensors, Inc. is a privately held company developing novel technologies for the rapid detection of pathogens in biodefense applications and human clinical diagnostics. IBI's technology has been tailored to rapidly and sensitively detect biological threats in building security, military, and civil defense applications. Additionally, the technology platform is being used to develop rapid tests for the detection of hospital-acquired infections. Additional information is available at Innovative Biosensors, Inc. (IBI). (http://www.innovativebiosensors.com/)

About Universal Detection Technology

Universal Detection Technology is a developer of monitoring technologies, including bioterrorism detection devices. The Company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. For example, the Company, in cooperation with NASA, has developed a bio-terror 'smoke' detector that detects certain bio hazard substances. For more information, please visit http://www.udetection.com.

This release may contain forward-looking statements that are subject to certain risks and uncertainties, including Innovative Biosensors, Inc.'s mission to develop and commercialize instrument systems, Innovative Biosensors, Inc.'s ability to develop new technologies to conduct rapid diagnosis. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Innovative Biosensors, Inc. cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: Innovative Biosensors, Inc.'s expectations that they will incur operating losses in the near future, the early stage of preclinical and clinical testing and trials, uncertainties surrounding the availability of additional funding, Innovative Biosensors, Inc.'s reliance on research collaborations, the actions of competitors and the development of competing technologies, potential patent infringement claims against Innovative Biosensors, Inc.'s products, processes and technologies, Innovative Biosensors, Inc.'s ability to protect their patents and proprietary rights and uncertainties relating to commercialization rights.